Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
21-40 of 991 trials

Systemic Lupus Erythematosus: Deucravacitinib Study

We are evaluating a new medication, deucravacitinib, for individuals with active systemic lupus erythematosus. The study aims to determine if it is more effective than a placebo in reducing disease symptoms and improving overall health.

Active Systemic Lupus Erythematosus1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementRheumatology

IgG4-Related Disease: Obexelimab Treatment Study

We are studying a new medication, obexelimab, for people with IgG4-related disease to see if it helps prevent flare-ups after steroid treatment. We will also check how safe and well-tolerated it is for patients.

IgG4-Related Disease1-2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInfectious DiseasesRheumatology

HER2+ Breast Cancer: Tucatinib with Oral Etoposide and Trastuzumab

We are studying a new treatment combining tucatinib, oral etoposide, and trastuzumab for patients with metastatic HER2+ breast cancer who have not responded to prior therapies. The goal is to see if this combination improves treatment outcomes and safety.

Metastatic HER2+ Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Morphine Study in Obesity and Sleep Apnea Patients

We are investigating how obesity and obstructive sleep apnea influence the effects of morphine for pain relief. This research aims to improve pain management for patients, especially those having bariatric surgery.

Obesity Surgery>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementEndocrinologyInternal MedicineOrthopedics and TraumatologyOtolaryngologyPsychiatry

Multiple Myeloma: Anti-BCMA CAR T Cell Therapy

We are studying a new CAR T cell treatment for patients with relapsed or refractory Multiple Myeloma. The trial aims to evaluate its safety and effectiveness in improving patient outcomes.

Relapsed/Refractory Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Advanced Non-Small Cell Lung Cancer: Datopotamab Deruxtecan and Pembrolizumab

We are studying a new treatment combination for patients with advanced non-small cell lung cancer who have not had prior therapy. The goal is to see if this combination works better than standard treatments in improving survival and reducing disease progression.

Advanced Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Melanoma Treatment: Nivolumab + Relatlimab Injection Study

We are comparing a new way to give a combination treatment for advanced melanoma to see if it works as well as the traditional method. This study is for people who have not yet been treated for their melanoma.

Metastatic MelanomaConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementDermatologyOncology

Cirrhosis and Ascites: Personalized Human Albumin Treatment

We are studying a tailored approach to human albumin therapy for patients with liver cirrhosis and fluid buildup. The goal is to identify who may respond best to this treatment.

Liver Cirrhosis>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesCost ReimbursementHepatologyInternal Medicine

Early Breast Cancer: Imlunestrant vs Standard Therapy

We are studying a new treatment called imlunestrant for patients with early breast cancer who have already received 2 to 5 years of standard therapy. The goal is to see if it helps reduce the risk of cancer returning compared to current treatments.

Breast Cancer>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Early Breast Cancer: Camizestrant vs. Standard Therapy

We are studying whether the new medication camizestrant can better prevent breast cancer recurrence in patients who have completed initial treatment. This trial involves individuals with ER+/HER2- early breast cancer at risk of returning after standard therapy.

ER+/HER2- Early Breast Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Fanconi Anemia: Long-Term Study of RP-L102 Infusion

We are evaluating the long-term safety and health effects of a gene therapy infusion for patients with Fanconi Anemia. This study looks at blood health and potential risks over time.

Fanconi's AnemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost Reimbursement

Biliary Atresia: Long-term Study of Odevixibat

We are studying the long-term effects of odevixibat in children with biliary atresia to see if it helps improve liver health and overall growth. The trial also looks at the safety of this treatment over time.

Biliary Atresia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHepatologyPediatrics

Infantile-onset Pompe Disease: Cipaglucosidase Alfa/Miglustat Study

We are evaluating a new treatment for children under 18 with infantile-onset Pompe disease to see if it is safe and effective. This study includes both children who have and have not received previous enzyme replacement therapy.

Pompe's Disease (Infantile Onset)>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineNeurologyPediatrics

Migraine Prevention: Atogepant for Kids

We are studying the long-term safety and tolerability of atogepant in children and teens aged 6 to 17 with migraines. This research aims to ensure the treatment is safe for young patients.

Migraine1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Episodic Migraine: Atogepant for Kids and Teens

We are studying the safety and effectiveness of Atogepant tablets for children and teens aged 6 to 17 with episodic migraines. This trial compares the medication to a placebo to see if it helps reduce migraine symptoms.

Episodic Migraine3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Ulcerative Colitis: GS-5290 Medication Study

We are testing a new medication for people with moderately to severely active ulcerative colitis to see if it helps improve symptoms better than a placebo. The study will assess various measures of clinical response and remission.

Ulcerative Colitis1-2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Stroke Prevention: Milvexian Study

We are testing a new oral medication, milvexian, for individuals who have had an acute ischemic stroke or high-risk transient ischemic attack. The study aims to see if it can lower the risk of future strokes and other heart-related issues.

Acute Ischemic Stroke and High-Risk Transient Ischemic Attack>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Heart Failure in Children: Vericiguat Study

We are studying a new medication, vericiguat, to see if it helps improve heart function in children with heart failure. The trial compares its effects to a placebo to ensure safety and effectiveness.

Chronic Systolic Heart FailureEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPediatrics

Cancer Treatment: Long-term Study of Pembrolizumab

We are evaluating the long-term safety and survival of patients currently on pembrolizumab treatment. This study aims to understand how well the treatment works and its effects over time.

Advanced Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Severe Pneumonia: Testing Trimodulin

We are studying whether trimodulin can improve survival in hospitalized adults with severe pneumonia compared to a placebo. The trial also looks at the safety and effects of the treatment.

Community Acquired PneumoniaConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology